These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2050288

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.
    Norman JA, Ansell J, Stone GA, Wennogle LP, Wasley JW.
    Mol Pharmacol; 1987 May; 31(5):535-40. PubMed ID: 3033469
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of gastric acid secretion in vivo and in vitro by a new calmodulin antagonist, CGS 9343B.
    Black EW, Strada SJ, Garrett RL, Kvietys PR, Thompson WJ, Norman JA.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):208-14. PubMed ID: 2464057
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of membrane currents and rises of intracellular Ca2+ in PC12 cells by CGS 9343B, a calmodulin inhibitor.
    Neuhaus R, Reber BF.
    Eur J Pharmacol; 1992 Jun 05; 226(2):183-5. PubMed ID: 1379190
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CGS 9343B and W7 (calmodulin antagonists) inhibit KCl-induced increase in cytosolic free calcium and insulin secretion of RINm5F cells.
    Safayhi H, Kühn M, Koopmann I, Ammon HP.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jun 05; 339(1-2):8-13. PubMed ID: 2657441
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of voltage-gated Ca2+ channels and insulin secretion in HIT cells by the Ca2+/calmodulin-dependent protein kinase II inhibitor KN-62: comparison with antagonists of calmodulin and L-type Ca2+ channels.
    Li G, Hidaka H, Wollheim CB.
    Mol Pharmacol; 1992 Sep 05; 42(3):489-8. PubMed ID: 1328847
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A novel calmodulin antagonist, CGS 9343B, modulates calcium-dependent changes in neurite outgrowth and growth cone movements.
    Polak KA, Edelman AM, Wasley JW, Cohan CS.
    J Neurosci; 1991 Feb 05; 11(2):534-42. PubMed ID: 1992015
    [Abstract] [Full Text] [Related]

  • 18. Effects of Ca(2+)-ionophore A23187 and calmodulin antagonists on regulatory mechanisms of glycolysis and cell viability of NIH-3T3 fibroblasts.
    Ashkenazy-Shahar M, Beitner R.
    Mol Genet Metab; 1999 Aug 05; 67(4):334-42. PubMed ID: 10444344
    [Abstract] [Full Text] [Related]

  • 19. Treatment of muscle damage, induced by high intracellular Ca2+, with calmodulin antagonists.
    Beitner R, Lilling G.
    Gen Pharmacol; 1993 Jul 05; 24(4):847-55. PubMed ID: 8224738
    [Abstract] [Full Text] [Related]

  • 20. Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells.
    Glass-Marmor L, Morgenstern H, Beitner R.
    Eur J Pharmacol; 1996 Oct 17; 313(3):265-71. PubMed ID: 8911923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.